Industry
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.
India’s youngest airline Akasa Air seeks funds as Iran war drives up costs
Akasa Air is raising funds through equity and debt to navigate industry challenges. The airline seeks eight billion rupees from investors and two point five billion rupees in loans. Existing owners will contribute five billion rupees to the equity portion. Despite headwinds, Akasa Air has expanded its operations locally. The company plans further capacity increases in the coming year.
170-year-old mosque may be shifted for Kolkata airport expansion
BSNL operational revenue grows 10% in June quarter
Lessors aim to reclaim SpiceJet aircraft due to increasing unpaid rentals
Warburg, Bain, CVC among PE firms in talks to buy into Agappe Diagnostics
Aditya Birla Renewables Acquires Sprng Energy
NCLT refuses to reinstate Juliet Apparels founder Gunvant Trevadia as Director